Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPAX 002 in Gulf War Illness
NCT02357030Phase 2Unknown
- Sponsor
- K-PAX Pharmaceuticals, Inc.
- Start
- Jan 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methylphenidate hydrochloride extended-release chewable tablet in Gulf War syndrome (GWS), sponsored by K-PAX Pharmaceuticals, Inc. Primary endpoint: Checklist Individual Strength Total Score at 12 weeks. Status: unknown.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
Gulf War syndrome (GWS)
Beyond the preview
Go deeper on NCT02357030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02357030.